Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$719 Mln
P/E Ratio
--
P/B Ratio
2.83
Industry P/E
--
Debt to Equity
-9.78
ROE
-2.38 %
ROCE
-118.19 %
Div. Yield
0 %
Book Value
--
EPS
-4.92
CFO
$-461.18 Mln
EBITDA
$-590.69 Mln
Net Profit
$-718.97 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Uniqure NV (QURE)
| -16.11 | 8.14 | -3.11 | 207.37 | -2.88 | -23.36 | -5.52 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Uniqure NV (QURE)
| -70.14 | 9.31 | -42.60 | -49.58 | 148.65 | 46.81 | 249.82 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 4.49 | 515.37 | 26.5 | 3.8 | |
| 42.43 | 2,974.69 | -- | -31.35 | |
| 1.46 | 138.88 | -- | -42.73 | |
| 42.57 | 8,748.38 | 106.53 | 2.27 |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.... Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Address: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP Read more
CEO & Executive Director
Mr. Matthew Craig Kapusta
CEO & Executive Director
Mr. Matthew Craig Kapusta CPA
Headquarters
Amsterdam
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Uniqure NV (QURE) stood at $ 557 Mln as on 31-Dec-24
The share price of Uniqure NV (QURE) is $14.82 (NASDAQ) as of 23-Apr-2025 13:38 EDT. Uniqure NV (QURE) has given a return of -2.88% in the last 3 years.
Uniqure NV (QURE) has a market capitalisation of $ 719 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Uniqure NV (QURE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Uniqure NV (QURE) and enter the required number of quantities and click on buy to purchase the shares of Uniqure NV (QURE).
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. Address: Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP
The CEO & director of Mr. Matthew Craig Kapusta. is Uniqure NV (QURE), and CFO & Sr. VP is Mr. Matthew Craig Kapusta CPA.
There is no promoter pledging in Uniqure NV (QURE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,026
|
|
|
296
|
|
|
91
|
|
|
36
|
| Uniqure NV (QURE) | Ratios |
|---|---|
|
Return on equity(%)
|
-238.46
|
|
Operating margin(%)
|
-639.35
|
|
Net Margin(%)
|
-883.35
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Uniqure NV (QURE) was $0 Mln.
$0.43
(
